rifampicin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, rifamycin derivatives 2377 13292-46-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rifampicin
  • rifampin
  • refampicin
  • rifadin
  • rifadine
  • rifaldazine
  • rifaldin
  • rifaprodin
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
  • Molecular weight: 822.95
  • Formula: C43H58N4O12
  • CLOGP: 2.49
  • LIPINSKI: 3
  • HAC: 16
  • HDO: 6
  • TPSA: 220.15
  • ALOGS: -4.30
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O
0.60 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.97 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.80 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 1.40 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 21, 1971 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 1258.80 15.76 452 19483 33384 63435703
Paradoxical drug reaction 582.74 15.76 154 19781 3998 63465089
Drug interaction 567.63 15.76 511 19424 228620 63240467
Drug resistance 513.33 15.76 212 19723 22721 63446366
Drug-induced liver injury 405.26 15.76 214 19721 40008 63429079
Eosinophilia 363.94 15.76 166 19769 22590 63446497
Acute hepatic failure 247.54 15.76 119 19816 18208 63450879
Jaundice 195.32 15.76 119 19816 29132 63439955
Tuberculoma of central nervous system 184.61 15.76 38 19897 309 63468778
Rash maculo-papular 168.69 15.76 112 19823 31784 63437303
Acute kidney injury 161.42 15.76 293 19642 263122 63205965
Immune reconstitution inflammatory syndrome 159.24 15.76 63 19872 6021 63463066
Pathogen resistance 142.51 15.76 59 19876 6339 63462748
Tuberculosis 139.94 15.76 69 19866 11142 63457945
Cholestasis 128.83 15.76 92 19843 29342 63439745
Pyrexia 118.69 15.76 370 19565 470108 62998979
Hepatocellular injury 113.93 15.76 83 19852 27298 63441789
Virologic failure 112.95 15.76 36 19899 1826 63467261
Hepatitis 108.36 15.76 94 19841 39694 63429393
Immune reconstitution inflammatory syndrome associated tuberculosis 104.07 15.76 24 19911 346 63468741
Hepatotoxicity 103.90 15.76 89 19846 36952 63432135
Drug ineffective for unapproved indication 102.03 15.76 85 19850 33978 63435109
Hepatic encephalopathy 88.62 15.76 51 19884 11231 63457856
Drug level decreased 84.96 15.76 44 19891 7875 63461212
Product use in unapproved indication 82.56 15.76 177 19758 178903 63290184
Pancreatitis haemorrhagic 75.84 15.76 20 19915 513 63468574
Hepatic cytolysis 74.02 15.76 51 19884 15356 63453731
Pulmonary tuberculosis 69.16 15.76 32 19903 4485 63464602
Optic neuropathy 67.36 15.76 25 19910 2007 63467080
Hidradenitis 65.94 15.76 27 19908 2819 63466268
Thrombocytopenia 64.64 15.76 145 19790 151012 63318075
Hepatic failure 64.15 15.76 67 19868 35589 63433498
Transaminases increased 61.98 15.76 62 19873 31305 63437782
Choroiditis 61.90 15.76 14 19921 184 63468903
Fatigue 59.15 15.76 119 19816 887909 62581178
Renal tubular necrosis 58.67 15.76 40 19895 11838 63457249
Pregnancy with implant contraceptive 57.24 15.76 24 19911 2659 63466428
Type 2 lepra reaction 56.81 15.76 10 19925 30 63469057
Alopecia 56.27 15.76 18 19917 337518 63131569
Pain 55.74 15.76 92 19843 740536 62728551
Glomerulonephritis minimal lesion 53.25 15.76 13 19922 242 63468845
Distributive shock 53.24 15.76 19 19916 1364 63467723
Fall 51.03 15.76 30 19905 392304 63076783
Sinusitis 50.43 15.76 6 19929 226647 63242440
Mechanical urticaria 49.71 15.76 14 19921 462 63468625
Hepatic function abnormal 48.37 15.76 59 19876 37083 63432004
Anticoagulation drug level decreased 48.36 15.76 9 19926 40 63469047
Mycobacterium avium complex infection 47.66 15.76 22 19913 3066 63466021
Labelled drug-drug interaction medication error 45.52 15.76 36 19899 13363 63455724
Cystic fibrosis pancreatic 45.42 15.76 9 19926 59 63469028
Hepatitis fulminant 45.25 15.76 22 19913 3442 63465645
Infusion related reaction 44.78 15.76 11 19924 245510 63223577
Tuberculosis gastrointestinal 43.67 15.76 12 19923 361 63468726
Oligoarthritis 42.87 15.76 13 19922 558 63468529
Nasopharyngitis 41.57 15.76 14 19921 254243 63214844
Contraindicated product administered 41.18 15.76 9 19926 217639 63251448
Vascular purpura 41.12 15.76 16 19919 1462 63467625
Multiple organ dysfunction syndrome 40.95 15.76 68 19867 56684 63412403
Oedematous kidney 40.32 15.76 9 19926 111 63468976
Headache 40.24 15.76 87 19848 633154 62835933
Face oedema 40.02 15.76 40 19895 20172 63448915
Immunosuppressant drug level decreased 40.00 15.76 14 19921 949 63468138
Disseminated tuberculosis 39.85 15.76 19 19916 2848 63466239
Hyperbilirubinaemia 39.73 15.76 31 19904 11283 63457804
Focal dyscognitive seizures 39.51 15.76 19 19916 2902 63466185
Status epilepticus 39.47 15.76 35 19900 15198 63453889
Jarisch-Herxheimer reaction 38.97 15.76 11 19924 366 63468721
Atypical mycobacterial infection 38.18 15.76 14 19921 1086 63468001
Urinary tract infection 37.68 15.76 18 19917 264666 63204421
Aspergillus infection 37.02 15.76 26 19909 8067 63461020
Systemic lupus erythematosus 36.87 15.76 10 19925 208908 63260179
Arthropathy 36.56 15.76 14 19921 234778 63234309
Optic neuritis 36.05 15.76 26 19909 8409 63460678
Abdominal discomfort 35.77 15.76 29 19906 320856 63148231
Constipation 35.71 15.76 13 19922 224930 63244157
Acute respiratory distress syndrome 34.97 15.76 40 19895 23494 63445593
Tubo-ovarian abscess 34.49 15.76 10 19925 367 63468720
Oedematous pancreatitis 34.28 15.76 11 19924 570 63468517
Drug eruption 33.24 15.76 43 19892 28651 63440436
Blood creatine phosphokinase increased 32.78 15.76 44 19891 30386 63438701
Metabolic acidosis 32.51 15.76 54 19881 45015 63424072
Joint swelling 32.48 15.76 33 19902 327633 63141454
Wound 32.44 15.76 6 19929 163257 63305830
Peripheral swelling 32.25 15.76 22 19913 265920 63203167
Eosinophil count increased 32.14 15.76 27 19908 10901 63458186
Hypertransaminasaemia 32.03 15.76 22 19913 6587 63462500
Product dose omission issue 31.75 15.76 17 19918 234296 63234791
Aspartate aminotransferase increased 31.42 15.76 80 19855 90197 63378890
Alanine aminotransferase increased 31.10 15.76 87 19848 103683 63365404
Pain in extremity 31.06 15.76 35 19900 331451 63137636
Linear IgA disease 31.02 15.76 13 19922 1438 63467649
Rheumatoid arthritis 29.46 15.76 22 19913 253797 63215290
Drug ineffective 29.42 15.76 475 19460 1044290 62424797
Dermatitis exfoliative generalised 29.33 15.76 17 19918 3790 63465297
Skin odour abnormal 29.30 15.76 13 19922 1653 63467434
Adrenocortical insufficiency acute 29.06 15.76 13 19922 1685 63467402
Blood alkaline phosphatase increased 29.02 15.76 50 19885 42917 63426170
Eosinophilic pneumonia acute 29.02 15.76 9 19926 417 63468670
Rash morbilliform 28.72 15.76 16 19919 3309 63465778
Skin reaction 28.68 15.76 29 19906 14820 63454267
Mycobacterial infection 28.45 15.76 13 19922 1770 63467317
Generalised onset non-motor seizure 28.41 15.76 5 19930 15 63469072
Discomfort 27.72 15.76 9 19926 167365 63301722
Disseminated intravascular coagulation 27.66 15.76 32 19903 19019 63450068
Chromaturia 27.56 15.76 30 19905 16687 63452400
Palmoplantar pustulosis 27.37 15.76 9 19926 504 63468583
Coagulopathy 27.34 15.76 33 19902 20511 63448576
Bullous haemorrhagic dermatosis 27.19 15.76 6 19929 70 63469017
Anuria 27.01 15.76 26 19909 12525 63456562
Multiple-drug resistance 26.94 15.76 18 19917 5152 63463935
Hepatitis cholestatic 26.68 15.76 20 19915 6858 63462229
Cholestatic liver injury 26.56 15.76 14 19921 2596 63466491
Staphylococcal infection 26.55 15.76 47 19888 41209 63427878
Vomiting 26.45 15.76 280 19655 559337 62909750
Renal impairment 26.40 15.76 74 19861 88281 63380806
Blood bilirubin increased 26.12 15.76 44 19891 37096 63431991
Anti-cyclic citrullinated peptide antibody positive 26.02 15.76 3 19932 116209 63352878
Alagille syndrome 25.50 15.76 4 19931 4 63469083
Premature labour 25.22 15.76 25 19910 12479 63456608
Therapy naive 25.20 15.76 5 19930 33 63469054
Agranulocytosis 25.04 15.76 35 19900 25099 63443988
Contusion 24.97 15.76 8 19927 150036 63319051
Crystalluria 24.92 15.76 8 19927 415 63468672
Tubulointerstitial nephritis 24.91 15.76 31 19904 19872 63449215
Off label use 24.59 15.76 321 19614 674141 62794946
Pigment nephropathy 24.59 15.76 5 19930 38 63469049
Purpura non-thrombocytopenic 24.36 15.76 6 19929 116 63468971
Vanishing bile duct syndrome 24.24 15.76 9 19926 723 63468364
Clostridium difficile colitis 24.10 15.76 31 19904 20538 63448549
Lymphadenopathy 23.71 15.76 43 19892 38415 63430672
Hepatitis toxic 23.68 15.76 14 19921 3239 63465848
Breast discomfort 23.53 15.76 8 19927 497 63468590
Dizziness 23.35 15.76 64 19871 429861 63039226
Respiratory symptom 23.31 15.76 14 19921 3333 63465754
Pancytopenia 23.13 15.76 75 19860 96858 63372229
Granuloma 22.90 15.76 17 19918 5744 63463343
Toxic skin eruption 22.79 15.76 24 19911 12861 63456226
Intentional product use issue 22.78 15.76 6 19929 127886 63341201
Exfoliative rash 22.70 15.76 13 19922 2834 63466253
Haemolysis 22.59 15.76 18 19917 6750 63462337
Type IV hypersensitivity reaction 22.49 15.76 13 19922 2885 63466202
Death 22.44 15.76 53 19882 374328 63094759
Mastitis bacterial 22.30 15.76 5 19930 63 63469024
Human herpesvirus 6 infection 22.24 15.76 13 19922 2944 63466143
Dyspnoea 22.04 15.76 120 19815 661193 62807894
Pericarditis 21.92 15.76 7 19928 131572 63337515
Hydrocephalus 21.88 15.76 16 19919 5284 63463803
Erythema multiforme 21.76 15.76 21 19914 10148 63458939
Toxic optic neuropathy 21.57 15.76 6 19929 189 63468898
Liver injury 21.43 15.76 54 19881 60466 63408621
Leukopenia 21.41 15.76 63 19872 77227 63391860
Enterovirus infection 21.40 15.76 9 19926 1005 63468082
Limbal swelling 21.28 15.76 4 19931 19 63469068
Condition aggravated 21.24 15.76 206 19729 402011 63067076
Mixed liver injury 21.16 15.76 15 19920 4720 63464367
Latent tuberculosis 20.96 15.76 12 19923 2615 63466472
Anticoagulation drug level below therapeutic 20.76 15.76 8 19927 712 63468375
Immune system disorder 20.46 15.76 20 19915 9814 63459273
Cryptococcosis 20.25 15.76 9 19926 1148 63467939
Haemolytic anaemia 19.97 15.76 20 19915 10105 63458982
Swelling 19.88 15.76 35 19900 275343 63193744
Skin lesion 19.77 15.76 35 19900 30686 63438401
Purpura 19.77 15.76 21 19914 11364 63457723
Nosocomial infection 19.72 15.76 10 19925 1711 63467376
Unintended pregnancy 19.70 15.76 16 19919 6163 63462924
Nephropathy toxic 19.20 15.76 19 19916 9460 63459627
Tuberculosis of eye 19.17 15.76 4 19931 35 63469052
Folate deficiency 18.93 15.76 11 19924 2464 63466623
Ototoxicity 18.85 15.76 9 19926 1353 63467734
White matter lesion 18.82 15.76 10 19925 1885 63467202
Hepatic necrosis 18.71 15.76 15 19920 5672 63463415
Back pain 18.68 15.76 34 19901 264111 63204976
Endocarditis 18.57 15.76 15 19920 5735 63463352
Bronchitis 18.53 15.76 8 19927 124927 63344160
Acute generalised exanthematous pustulosis 18.44 15.76 20 19915 11079 63458008
Synovitis 18.30 15.76 19 19916 186899 63282188
Anxiety 18.23 15.76 25 19910 217516 63251571
Epstein-Barr virus test positive 18.22 15.76 7 19928 618 63468469
Orbital infection 18.02 15.76 4 19931 48 63469039
Post treatment Lyme disease syndrome 17.91 15.76 3 19932 6 63469081
Eyelid oedema 17.61 15.76 19 19916 10460 63458627
Pancreatitis 17.61 15.76 44 19891 49011 63420076
Hyperleukocytosis 17.59 15.76 7 19928 679 63468408
Muscle spasms 17.51 15.76 14 19921 156136 63312951
Gamma-glutamyltransferase increased 17.23 15.76 35 19900 33996 63435091
Rebound effect 17.20 15.76 13 19922 4513 63464574
Bile duct necrosis 17.04 15.76 3 19932 9 63469078
Rheumatoid factor positive 16.98 15.76 3 19932 84403 63384684
Wound secretion 16.98 15.76 13 19922 4601 63464486
Visual acuity reduced 16.88 15.76 27 19908 21799 63447288
Type 1 lepra reaction 16.80 15.76 3 19932 10 63469077
Neutropenia 16.72 15.76 103 19832 174902 63294185
Pneumatosis intestinalis 16.56 15.76 10 19925 2403 63466684
Disseminated cytomegaloviral infection 16.53 15.76 5 19930 213 63468874
Loss of personal independence in daily activities 16.52 15.76 5 19930 97285 63371802
Encephalopathy 16.42 15.76 37 19898 38583 63430504
Scar excision 16.36 15.76 4 19931 75 63469012
Glomerular filtration rate abnormal 16.22 15.76 7 19928 832 63468255
Acid fast bacilli infection 16.16 15.76 4 19931 79 63469008
Skin hyperpigmentation 16.13 15.76 14 19921 5907 63463180
Cheilitis 16.04 15.76 12 19923 4101 63464986
International normalised ratio abnormal 16.01 15.76 11 19924 3293 63465794
Lower respiratory tract infection 15.95 15.76 11 19924 132296 63336791

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 1047.58 16.09 270 21428 3081 34932152
Drug reaction with eosinophilia and systemic symptoms 909.35 16.09 432 21266 32580 34902653
Drug-induced liver injury 409.93 16.09 243 21455 28589 34906644
Drug resistance 364.55 16.09 217 21481 25710 34909523
Immune reconstitution inflammatory syndrome 350.22 16.09 149 21549 8610 34926623
Drug interaction 309.03 16.09 523 21175 225423 34709810
Hepatotoxicity 243.94 16.09 157 21541 21328 34913905
Jaundice 235.58 16.09 179 21519 31703 34903530
Rash maculo-papular 197.60 16.09 154 21544 28297 34906936
Eosinophilia 193.18 16.09 147 21551 26075 34909158
Immune reconstitution inflammatory syndrome associated tuberculosis 163.15 16.09 41 21657 417 34934816
Drug level decreased 146.12 16.09 79 21619 7767 34927466
Acute kidney injury 139.43 16.09 460 21238 304528 34630705
Type 2 lepra reaction 135.53 16.09 30 21668 165 34935068
Hypoprothrombinaemia 130.14 16.09 33 21665 349 34934884
Hepatocellular injury 122.16 16.09 105 21593 22106 34913127
Cholestasis 112.23 16.09 109 21589 26839 34908394
Optic neuropathy 111.45 16.09 43 21655 1922 34933311
Tubulointerstitial nephritis 108.78 16.09 96 21602 20928 34914305
Thrombocytopenia 108.28 16.09 274 21424 155973 34779260
Tuberculosis 100.55 16.09 64 21634 8513 34926720
Pyrexia 95.83 16.09 434 21264 332579 34602654
Mycobacterial infection 93.56 16.09 40 21658 2334 34932899
Hepatitis 90.84 16.09 92 21606 23812 34911421
Cardiac valve vegetation 89.92 16.09 26 21672 465 34934768
Condition aggravated 86.68 16.09 289 21409 191907 34743326
Immune system disorder 85.59 16.09 48 21650 5067 34930166
Drug ineffective 85.25 16.09 528 21170 456223 34479010
Vascular purpura 83.67 16.09 34 21664 1744 34933489
Pathogen resistance 82.95 16.09 59 21639 9423 34925810
Death 78.65 16.09 79 21619 397970 34537263
Tuberculoma of central nervous system 76.26 16.09 20 21678 244 34934989
Jarisch-Herxheimer reaction 72.56 16.09 23 21675 568 34934665
Fall 69.39 16.09 20 21678 202865 34732368
Drug ineffective for unapproved indication 61.93 16.09 75 21623 23640 34911593
Vitamin K deficiency 61.71 16.09 17 21681 253 34934980
Granuloma 61.26 16.09 33 21665 3218 34932015
Alveolar lung disease 59.99 16.09 18 21680 368 34934865
Eosinophilic pneumonia 58.97 16.09 33 21665 3468 34931765
Hydrocephalus 58.74 16.09 38 21660 5194 34930039
Hepatic failure 57.83 16.09 88 21610 34443 34900790
Multiple-drug resistance 56.25 16.09 37 21661 5202 34930031
Treatment failure 54.19 16.09 101 21597 46596 34888637
Tuberculosis of central nervous system 51.81 16.09 14 21684 193 34935040
Liver function test abnormal 51.76 16.09 79 21619 30995 34904238
Pulmonary interstitial emphysema syndrome 50.59 16.09 17 21681 507 34934726
Fatigue 50.58 16.09 96 21602 370557 34564676
Type 1 lepra reaction 50.01 16.09 10 21688 30 34935203
Lymphadenopathy 49.74 16.09 74 21624 28389 34906844
Purpura 49.20 16.09 45 21653 10266 34924967
Completed suicide 48.98 16.09 3 21695 98165 34837068
Hypovitaminosis 48.34 16.09 17 21681 583 34934650
Hepatic function abnormal 47.83 16.09 93 21605 44270 34890963
Optic neuritis 47.78 16.09 29 21669 3545 34931688
Skin disorder 47.56 16.09 50 21648 13505 34921728
Linear IgA disease 46.82 16.09 22 21676 1604 34933629
Mycobacterium avium complex infection 45.95 16.09 25 21673 2486 34932747
Constipation 45.89 16.09 14 21684 136968 34798265
Myocardial infarction 45.09 16.09 10 21688 121075 34814158
Pulmonary tuberculosis 44.88 16.09 31 21667 4723 34930510
Febrile neutropenia 44.05 16.09 15 21683 136834 34798399
Immune thrombocytopenia 43.78 16.09 40 21658 9112 34926121
Acute hepatic failure 42.55 16.09 48 21650 14026 34921207
Meningitis tuberculous 42.48 16.09 16 21682 669 34934564
Drug abuse 41.62 16.09 6 21692 99090 34836143
Thalamic infarction 40.44 16.09 16 21682 765 34934468
Granulomatous liver disease 40.41 16.09 15 21683 602 34934631
Product use in unapproved indication 39.60 16.09 161 21537 117338 34817895
Hypersensitivity vasculitis 39.37 16.09 25 21673 3310 34931923
Haemolytic anaemia 39.19 16.09 40 21658 10439 34924794
Anticoagulation drug level decreased 38.99 16.09 10 21688 111 34935122
Diaphragmatic injury 37.83 16.09 10 21688 126 34935107
Transaminases increased 37.54 16.09 63 21635 26760 34908473
Toxic skin eruption 36.43 16.09 40 21658 11345 34923888
Tuberculosis of eye 36.14 16.09 8 21690 44 34935189
Pneumonia 34.51 16.09 113 21585 362514 34572719
Cross sensitivity reaction 34.46 16.09 17 21681 1380 34933853
Diffuse alveolar damage 34.12 16.09 20 21678 2294 34932939
Splenic embolism 34.07 16.09 10 21688 189 34935044
Dizziness 33.95 16.09 52 21646 218469 34716764
Product dose omission issue 32.31 16.09 17 21681 119694 34815539
Ocular toxicity 32.30 16.09 10 21688 228 34935005
Hidradenitis 32.27 16.09 15 21683 1067 34934166
Ototoxicity 32.09 16.09 18 21680 1899 34933334
Aortic valve prolapse 32.07 16.09 6 21692 11 34935222
Hepatic cytolysis 31.73 16.09 42 21656 14454 34920779
Cutaneous vasculitis 31.58 16.09 24 21674 4239 34930994
Sideroblastic anaemia 31.47 16.09 10 21688 249 34934984
Oliguria 31.36 16.09 32 21666 8348 34926885
Eosinophilic pneumonia acute 31.19 16.09 12 21686 532 34934701
Mycobacterium abscessus infection 31.19 16.09 12 21686 532 34934701
Hyperbilirubinaemia 31.17 16.09 45 21653 16798 34918435
Drug eruption 30.91 16.09 49 21649 19849 34915384
Cardiac failure congestive 30.74 16.09 7 21691 83263 34851970
Pain 30.56 16.09 50 21648 204625 34730608
Generalised oedema 30.38 16.09 38 21660 12370 34922863
Vascular pseudoaneurysm thrombosis 30.30 16.09 7 21691 48 34935185
Immunosuppressant drug level decreased 30.16 16.09 15 21683 1239 34933994
Dermatitis exfoliative generalised 29.98 16.09 22 21676 3685 34931548
Hepatic encephalopathy 29.79 16.09 41 21657 14644 34920589
Disseminated tuberculosis 29.75 16.09 18 21680 2187 34933046
Diarrhoea 29.67 16.09 133 21565 389779 34545454
Malignant neoplasm progression 29.47 16.09 9 21689 88037 34847196
Atrial fibrillation 29.35 16.09 20 21678 122373 34812860
Toxic epidermal necrolysis 29.17 16.09 50 21648 21596 34913637
Vitamin B1 decreased 28.85 16.09 10 21688 328 34934905
Coagulopathy 28.38 16.09 47 21651 19742 34915491
Central nervous system vasculitis 28.37 16.09 11 21687 498 34934735
Endocarditis 28.33 16.09 27 21671 6484 34928749
Lymphopenia 27.86 16.09 42 21656 16293 34918940
Hepatic enzyme increased 27.44 16.09 69 21629 39011 34896222
Leukopenia 26.87 16.09 93 21605 62763 34872470
Dyspnoea 26.61 16.09 132 21566 376650 34558583
Mycobacterium tuberculosis complex test positive 26.44 16.09 14 21684 1318 34933915
Cat scratch disease 26.11 16.09 8 21690 176 34935057
Type III immune complex mediated reaction 25.77 16.09 9 21689 302 34934931
Lymph node tuberculosis 25.74 16.09 10 21688 455 34934778
Atypical mycobacterial infection 25.46 16.09 12 21686 881 34934352
Coagulation factor X level decreased 25.26 16.09 5 21693 14 34935219
Drug level abnormal 25.18 16.09 8 21690 199 34935034
Hepatic necrosis 25.15 16.09 20 21678 3774 34931459
Stevens-Johnson syndrome 25.04 16.09 43 21655 18596 34916637
Shock haemorrhagic 25.01 16.09 33 21665 11321 34923912
Petechiae 24.92 16.09 30 21668 9388 34925845
Encephalopathy 24.42 16.09 62 21636 35257 34899976
Autoimmune haemolytic anaemia 24.18 16.09 21 21677 4475 34930758
Anxiety 24.17 16.09 16 21682 99412 34835821
Brain abscess 24.05 16.09 18 21680 3107 34932126
Splenic abscess 23.97 16.09 9 21689 373 34934860
Tuberculoid leprosy 23.96 16.09 6 21692 60 34935173
Nasopharyngitis 23.68 16.09 7 21691 69961 34865272
Bone tuberculosis 23.41 16.09 9 21689 398 34934835
Infective aneurysm 23.20 16.09 10 21688 595 34934638
Tendon disorder 23.11 16.09 17 21681 2858 34932375
Blood pressure increased 23.05 16.09 13 21685 88089 34847144
Jaundice cholestatic 23.02 16.09 21 21677 4773 34930460
Bradycardia 23.01 16.09 9 21689 75409 34859824
Atypical mycobacterium test positive 22.98 16.09 5 21693 25 34935208
Infusion related reaction 22.77 16.09 3 21695 53054 34882179
Candida infection 22.67 16.09 40 21658 17675 34917558
Thrombocytopenic purpura 22.32 16.09 12 21686 1165 34934068
Urinary tract inflammation 22.23 16.09 7 21691 169 34935064
Unmasking of previously unidentified disease 22.18 16.09 11 21687 903 34934330
Labelled drug-drug interaction medication error 22.12 16.09 36 21662 14903 34920330
Malaise 21.22 16.09 53 21645 185772 34749461
Dehydration 21.06 16.09 30 21668 129939 34805294
Pulmonary sequestration 20.97 16.09 5 21693 40 34935193
Staphylococcal bacteraemia 20.87 16.09 26 21672 8426 34926807
Leprosy 20.77 16.09 6 21692 107 34935126
Eosinophilic myocarditis 20.76 16.09 9 21689 543 34934690
Antimicrobial susceptibility test resistant 20.55 16.09 8 21690 366 34934867
Vasculitis necrotising 20.29 16.09 10 21688 810 34934423
Asthenia 20.24 16.09 81 21617 245170 34690063
Cerebrovascular accident 20.14 16.09 14 21684 84797 34850436
Coronary artery disease 20.09 16.09 3 21695 48302 34886931
Staphylococcal infection 20.09 16.09 55 21643 32705 34902528
Tuberculosis gastrointestinal 19.99 16.09 7 21691 237 34934996
Insomnia 19.98 16.09 21 21677 103886 34831347
Lactic acidosis 19.97 16.09 57 21641 34715 34900518
Pulmonary eosinophilia 19.85 16.09 7 21691 242 34934991
Hyperammonaemia 19.73 16.09 22 21676 6345 34928888
Hepatorenal syndrome 19.72 16.09 15 21683 2651 34932582
Pyroglutamic acidosis 19.54 16.09 8 21690 418 34934815
Depression 19.38 16.09 19 21679 97079 34838154
Choroiditis 19.24 16.09 11 21687 1204 34934029
Dilatation intrahepatic duct acquired 19.14 16.09 5 21693 60 34935173
Pulmonary cavitation 19.10 16.09 10 21688 920 34934313
Adrenocortical insufficiency acute 18.90 16.09 12 21686 1588 34933645
Rash 18.77 16.09 216 21482 222536 34712697
Feeling abnormal 18.55 16.09 8 21690 63227 34872006
Neutropenia 18.49 16.09 163 21535 156615 34778618
Conductive deafness 18.35 16.09 7 21691 303 34934930
Splenic infarction 18.35 16.09 13 21685 2062 34933171
Muscle spasms 18.31 16.09 12 21686 74989 34860244
Lichenoid keratosis 18.31 16.09 14 21684 2494 34932739
Renal tubular necrosis 18.28 16.09 34 21664 15646 34919587
Syncope 18.13 16.09 18 21680 91433 34843800
Headache 18.02 16.09 64 21634 200571 34734662
Dysbiosis 17.95 16.09 8 21690 516 34934717
Rash morbilliform 17.79 16.09 15 21683 3072 34932161
Axonal neuropathy 17.72 16.09 10 21688 1067 34934166
Agranulocytosis 17.71 16.09 43 21655 23778 34911455
Malabsorption from administration site 17.70 16.09 5 21693 82 34935151
Weight increased 17.66 16.09 19 21679 93014 34842219
Implant site infection 17.61 16.09 10 21688 1080 34934153
White blood cell count decreased 17.56 16.09 20 21678 95425 34839808
Protrusion tongue 17.42 16.09 6 21692 193 34935040
C-reactive protein increased 17.30 16.09 73 21625 54025 34881208
CD4/CD8 ratio decreased 17.24 16.09 4 21694 28 34935205
Trisomy 21 17.08 16.09 8 21690 579 34934654
Marrow hyperplasia 17.01 16.09 10 21688 1153 34934080
Pulmonary granuloma 16.90 16.09 11 21687 1519 34933714
COVID-19 16.87 16.09 14 21684 77536 34857697
Renal atrophy 16.84 16.09 10 21688 1175 34934058
Tuberculous pleurisy 16.83 16.09 7 21691 381 34934852
Testicular mass 16.81 16.09 5 21693 99 34935134
Influenza 16.75 16.09 5 21693 49661 34885572
Hypertransaminasaemia 16.74 16.09 19 21679 5587 34929646
Hemianopia heteronymous 16.56 16.09 4 21694 34 34935199
Neuropsychiatric symptoms 16.56 16.09 9 21689 893 34934340
Erythrodermic psoriasis 16.51 16.09 9 21689 898 34934335
Oral candidiasis 16.35 16.09 28 21670 12082 34923151
Chronic allograft nephropathy 16.29 16.09 10 21688 1247 34933986

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 2045.51 14.21 867 38332 63377 79641812
Paradoxical drug reaction 1549.69 14.21 411 38788 6774 79698415
Drug-induced liver injury 762.06 14.21 448 38751 65669 79639520
Drug interaction 711.41 14.21 943 38256 414240 79290949
Drug resistance 610.49 14.21 332 38867 41881 79663308
Eosinophilia 539.99 14.21 314 38885 45031 79660158
Immune reconstitution inflammatory syndrome 480.07 14.21 199 39000 13642 79691547
Jaundice 443.71 14.21 294 38905 53055 79652134
Rash maculo-papular 365.30 14.21 266 38933 55812 79649377
Hepatotoxicity 337.68 14.21 245 38954 51107 79654082
Acute kidney injury 312.30 14.21 746 38453 518658 79186531
Acute hepatic failure 269.91 14.21 174 39025 29939 79675250
Immune reconstitution inflammatory syndrome associated tuberculosis 269.68 14.21 66 39133 770 79704419
Drug level decreased 249.81 14.21 128 39071 14274 79690915
Cholestasis 234.98 14.21 199 39000 51910 79653279
Tuberculoma of central nervous system 234.09 14.21 55 39144 532 79704657
Hepatocellular injury 227.52 14.21 188 39011 47405 79657784
Tuberculosis 223.60 14.21 121 39078 15077 79690112
Pyrexia 211.79 14.21 772 38427 677937 79027252
Thrombocytopenia 180.83 14.21 401 38798 264858 79440331
Type 2 lepra reaction 177.71 14.21 37 39162 191 79704998
Optic neuropathy 165.88 14.21 63 39136 3421 79701768
Hepatitis 155.33 14.21 163 39036 55564 79649625
Pathogen resistance 138.75 14.21 87 39112 14255 79690934
Tubulointerstitial nephritis 136.51 14.21 128 39071 38107 79667082
Hypoprothrombinaemia 134.30 14.21 37 39162 705 79704484
Vascular purpura 126.13 14.21 50 39149 3048 79702141
Fall 123.31 14.21 43 39156 487586 79217603
Hepatic failure 121.24 14.21 150 39049 61062 79644127
Drug ineffective 118.92 14.21 921 38278 1079992 78625197
Drug ineffective for unapproved indication 113.65 14.21 133 39066 51105 79654084
Hepatic encephalopathy 112.41 14.21 94 39105 24072 79681117
Pulmonary tuberculosis 111.18 14.21 61 39138 7804 79697385
Immune system disorder 109.45 14.21 68 39131 10961 79694228
Fatigue 109.35 14.21 181 39018 929546 78775643
Mycobacterial infection 108.08 14.21 47 39152 3621 79701568
Hepatic function abnormal 106.22 14.21 154 39045 72953 79632236
Pain 100.63 14.21 119 39080 703683 79001506
Completed suicide 100.06 14.21 5 39194 245762 79459427
Jarisch-Herxheimer reaction 99.31 14.21 31 39168 926 79704263
Hepatic cytolysis 97.11 14.21 91 39108 27060 79678129
Cardiac valve vegetation 96.34 14.21 30 39169 889 79704300
Optic neuritis 82.78 14.21 54 39145 9466 79695723
Anticoagulation drug level decreased 82.19 14.21 19 39180 170 79705019
Headache 81.71 14.21 122 39077 653650 79051539
Lymphadenopathy 81.49 14.21 115 39084 53132 79652057
Transaminases increased 81.05 14.21 113 39086 51630 79653559
Nasopharyngitis 80.33 14.21 14 39185 253867 79451322
Infusion related reaction 79.05 14.21 10 39189 230227 79474962
Mycobacterium avium complex infection 77.20 14.21 40 39159 4560 79700629
Constipation 76.73 14.21 22 39177 283028 79422161
Linear IgA disease 75.89 14.21 35 39164 3097 79702092
Granuloma 74.45 14.21 48 39151 8249 79696940
Death 74.43 14.21 102 39097 566412 79138777
Hidradenitis 73.70 14.21 34 39165 3010 79702179
Type 1 lepra reaction 72.54 14.21 14 39185 45 79705144
Hyperbilirubinaemia 72.40 14.21 74 39125 24444 79680745
Condition aggravated 69.24 14.21 452 38747 500672 79204517
Eosinophilic pneumonia 69.09 14.21 39 39160 5271 79699918
Hydrocephalus 68.99 14.21 47 39152 8853 79696336
Purpura 68.97 14.21 65 39134 19462 79685727
Immunosuppressant drug level decreased 66.72 14.21 28 39171 1976 79703213
Disseminated tuberculosis 66.28 14.21 35 39164 4148 79701041
Choroiditis 65.84 14.21 25 39174 1356 79703833
Multiple-drug resistance 64.70 14.21 45 39154 8763 79696426
Haemolytic anaemia 64.25 14.21 60 39139 17760 79687429
Renal tubular necrosis 64.03 14.21 70 39129 24969 79680220
Dizziness 64.02 14.21 100 39099 526341 79178848
Meningitis tuberculous 61.76 14.21 23 39176 1182 79704007
Alopecia 60.84 14.21 19 39180 231336 79473853
Product dose omission issue 60.49 14.21 23 39176 247514 79457675
Atypical mycobacterial infection 60.20 14.21 25 39174 1718 79703471
Rheumatoid arthritis 58.75 14.21 15 39184 208455 79496734
Product use in unapproved indication 58.53 14.21 261 38938 250098 79455091
Drug abuse 58.50 14.21 6 39193 162685 79542504
Pancreatitis haemorrhagic 58.26 14.21 20 39179 810 79704379
Dermatitis exfoliative generalised 57.94 14.21 39 39160 7202 79697987
Alveolar lung disease 57.00 14.21 18 39181 559 79704630
Coagulopathy 56.93 14.21 79 39120 35927 79669262
Joint swelling 56.66 14.21 36 39163 288610 79416579
Eosinophilic pneumonia acute 56.43 14.21 21 39178 1077 79704112
Drug eruption 55.88 14.21 87 39112 43848 79661341
Peripheral swelling 55.19 14.21 32 39167 269585 79435604
Dyspnoea 55.03 14.21 226 38973 856799 78848390
Pulmonary interstitial emphysema syndrome 54.52 14.21 17 39182 506 79704683
Liver function test abnormal 53.74 14.21 106 39093 64369 79640820
Distributive shock 52.81 14.21 26 39173 2661 79702528
Toxic skin eruption 51.31 14.21 59 39140 22234 79682955
Tuberculosis of central nervous system 51.29 14.21 16 39183 477 79704712
Ototoxicity 50.76 14.21 27 39172 3247 79701942
Urinary tract infection 50.19 14.21 37 39162 274475 79430714
Tuberculosis gastrointestinal 48.89 14.21 16 39183 558 79704631
Labelled drug-drug interaction medication error 48.79 14.21 64 39135 27586 79677603
Leukopenia 48.00 14.21 146 39053 116367 79588822
Pain in extremity 47.44 14.21 66 39133 364472 79340717
Adrenocortical insufficiency acute 46.91 14.21 25 39174 3018 79702171
Eosinophil count increased 45.80 14.21 49 39150 17056 79688133
Arthropathy 45.75 14.21 15 39184 177096 79528093
Abdominal discomfort 45.56 14.21 34 39165 250693 79454496
Vitamin K deficiency 45.16 14.21 16 39183 712 79704477
Mechanical urticaria 44.63 14.21 14 39185 425 79704764
Myocardial infarction 43.51 14.21 18 39181 184111 79521078
Lymph node tuberculosis 43.50 14.21 17 39182 997 79704192
Status epilepticus 42.70 14.21 57 39142 24984 79680205
Encephalopathy 42.56 14.21 99 39100 67298 79637891
Insomnia 42.33 14.21 35 39164 245135 79460054
Granulomatous liver disease 42.30 14.21 18 39181 1315 79703874
Malignant neoplasm progression 41.91 14.21 8 39191 135982 79569207
Rash morbilliform 41.88 14.21 30 39169 6120 79699069
Pneumonia 41.75 14.21 175 39024 660071 79045118
Disseminated intravascular coagulation 41.49 14.21 68 39131 35774 79669415
Hepatic necrosis 41.49 14.21 35 39164 9065 79696124
Cystic fibrosis pancreatic 41.40 14.21 9 39190 59 79705130
Hypovitaminosis 41.37 14.21 17 39182 1137 79704052
Anxiety 41.06 14.21 37 39162 248475 79456714
Hypertransaminasaemia 40.79 14.21 39 39160 11885 79693304
Glomerulonephritis minimal lesion 40.26 14.21 15 39184 772 79704417
Diarrhoea 40.18 14.21 261 38938 880228 78824961
Diaphragmatic injury 40.15 14.21 10 39189 126 79705063
Wound 39.97 14.21 5 39194 116174 79589015
Agranulocytosis 39.92 14.21 76 39123 44954 79660235
Multiple organ dysfunction syndrome 39.91 14.21 140 39059 120106 79585083
Febrile neutropenia 39.85 14.21 33 39166 230966 79474223
Arthralgia 39.68 14.21 146 39053 571657 79133532
Bronchitis 39.60 14.21 8 39191 130636 79574553
Hepatitis fulminant 39.59 14.21 31 39168 7231 79697958
Metabolic acidosis 39.36 14.21 109 39090 82420 79622769
Thalamic infarction 39.33 14.21 17 39182 1290 79703899
Tuberculosis of eye 39.09 14.21 9 39190 79 79705110
Face oedema 39.00 14.21 58 39141 28078 79677111
Skin disorder 38.75 14.21 64 39135 33879 79671310
Hypersensitivity vasculitis 38.63 14.21 30 39169 6913 79698276
Brain abscess 38.10 14.21 26 39173 4910 79700279
Cholestatic liver injury 38.07 14.21 26 39173 4915 79700274
Immune thrombocytopenia 37.45 14.21 45 39154 17760 79687429
Influenza 37.13 14.21 9 39190 129597 79575592
Mycobacterium abscessus infection 37.12 14.21 16 39183 1206 79703983
Pregnancy with implant contraceptive 36.59 14.21 18 39181 1838 79703351
Splenic embolism 35.75 14.21 10 39189 202 79704987
Cardiac failure congestive 35.15 14.21 13 39186 142389 79562800
Type IV hypersensitivity reaction 35.12 14.21 23 39176 4058 79701131
Rash 35.04 14.21 436 38763 577922 79127267
Jaundice cholestatic 35.03 14.21 35 39164 11249 79693940
Alanine aminotransferase increased 34.63 14.21 165 39034 162405 79542784
Neutropenia 34.57 14.21 251 38948 287459 79417730
Liver injury 34.48 14.21 82 39117 56532 79648657
Contusion 34.41 14.21 15 39184 148761 79556428
Renal impairment 34.24 14.21 161 39038 157622 79547567
Oligoarthritis 34.13 14.21 13 39186 711 79704478
Oliguria 33.94 14.21 41 39158 16268 79688921
Autoimmune haemolytic anaemia 33.69 14.21 30 39169 8350 79696839
Stevens-Johnson syndrome 33.37 14.21 65 39134 39101 79666088
Contraindicated product administered 33.22 14.21 18 39181 157520 79547669
Endocarditis 33.14 14.21 33 39166 10564 79694625
Blood bilirubin increased 33.10 14.21 89 39110 66143 79639046
Sideroblastic anaemia 32.96 14.21 10 39189 271 79704918
Staphylococcal bacteraemia 32.71 14.21 35 39164 12183 79693006
Aortic valve prolapse 32.49 14.21 6 39193 14 79705175
Hepatitis cholestatic 32.45 14.21 37 39162 13815 79691374
Feeling abnormal 32.41 14.21 19 39180 159180 79546009
Tuberculoid leprosy 31.89 14.21 8 39191 104 79705085
Ocular toxicity 31.66 14.21 13 39186 868 79704321
Generalised oedema 31.62 14.21 48 39151 23661 79681528
Weight increased 31.50 14.21 55 39144 277331 79427858
Muscle spasms 31.34 14.21 24 39175 174706 79530483
Vascular pseudoaneurysm thrombosis 31.20 14.21 7 39192 54 79705135
Intentional product use issue 31.18 14.21 18 39181 152094 79553095
Intentional overdose 31.06 14.21 7 39192 105953 79599236
Oedematous kidney 31.03 14.21 9 39190 208 79704981
Tubo-ovarian abscess 31.00 14.21 10 39189 333 79704856
Asthma 30.65 14.21 14 39185 135081 79570108
Skin lesion 30.38 14.21 65 39134 41779 79663410
Diffuse alveolar damage 30.25 14.21 20 39179 3584 79701605
Mixed liver injury 30.21 14.21 27 39172 7551 79697638
Lymphopenia 30.14 14.21 54 39145 30503 79674686
Anti-cyclic citrullinated peptide antibody positive 30.05 14.21 3 39196 83140 79622049
Aspartate aminotransferase increased 29.73 14.21 141 39058 138500 79566689
Impaired healing 29.60 14.21 4 39195 87651 79617538
Bone tuberculosis 29.47 14.21 11 39188 569 79704620
Dehydration 29.29 14.21 48 39151 248139 79457050
Visual acuity reduced 28.96 14.21 52 39147 29417 79675772
Lactic acidosis 28.81 14.21 88 39111 70271 79634918
Staphylococcal infection 28.79 14.21 78 39121 58217 79646972
Toxic epidermal necrolysis 28.71 14.21 66 39133 44515 79660674
Pemphigus 28.36 14.21 7 39192 99575 79605614
Focal dyscognitive seizures 28.30 14.21 19 39180 3493 79701696
Cerebrovascular accident 28.27 14.21 21 39178 155271 79549918
Oedematous pancreatitis 28.13 14.21 13 39186 1155 79704034
Hepatitis toxic 28.12 14.21 22 39177 5125 79700064
Back pain 28.03 14.21 68 39131 304112 79401077
Thrombosis 28.02 14.21 4 39195 84096 79621093
Treatment failure 28.00 14.21 161 39038 170325 79534864
Memory impairment 27.92 14.21 10 39189 111724 79593465
Blood cholesterol increased 27.85 14.21 4 39195 83716 79621473
COVID-19 27.84 14.21 22 39177 157652 79547537
Stomatitis 27.83 14.21 19 39180 146738 79558451
Injection site erythema 27.80 14.21 3 39196 78194 79626995
Mycobacterium tuberculosis complex test positive 27.16 14.21 17 39182 2775 79702414
Discomfort 27.00 14.21 14 39185 125603 79579586
Lower respiratory tract infection 26.90 14.21 15 39184 129205 79575984
Pulmonary eosinophilia 26.85 14.21 11 39188 730 79704459
Blood pressure increased 26.74 14.21 39 39160 211321 79493868
Exfoliative rash 26.68 14.21 19 39180 3840 79701349
Pigment nephropathy 26.66 14.21 6 39193 47 79705142
Petechiae 26.53 14.21 41 39158 20524 79684665
Pancytopenia 26.23 14.21 155 39044 165590 79539599
Drug level below therapeutic 26.18 14.21 28 39171 9742 79695447
Vitamin B1 decreased 26.15 14.21 10 39189 553 79704636
Loss of personal independence in daily activities 25.94 14.21 9 39190 102571 79602618
Central nervous system vasculitis 25.82 14.21 13 39186 1395 79703794
Synovitis 25.42 14.21 22 39177 150712 79554477
Chest pain 25.31 14.21 64 39135 282240 79422949
Splenic infarction 25.24 14.21 18 39181 3646 79701543
Syncope 24.83 14.21 31 39168 179418 79525771
Acute generalised exanthematous pustulosis 24.53 14.21 36 39163 17218 79687971
Cutaneous vasculitis 24.53 14.21 25 39174 8227 79696962
Asthenia 24.12 14.21 150 39049 511539 79193650
Bradycardia 23.82 14.21 19 39180 135538 79569651
Depression 23.69 14.21 44 39155 216746 79488443
Pulmonary sequestration 23.67 14.21 5 39194 28 79705161
Infective aneurysm 23.60 14.21 11 39188 997 79704192
Lymphadenitis 23.51 14.21 19 39180 4636 79700553
Cachexia 23.29 14.21 28 39171 11055 79694134
Virologic failure 23.08 14.21 18 39181 4173 79701016
Vomiting 23.07 14.21 457 38742 665371 79039818
Hemianopia heteronymous 23.00 14.21 6 39193 92 79705097
Injury 22.96 14.21 5 39194 77491 79627698
Bullous haemorrhagic dermatosis 22.88 14.21 6 39193 94 79705095
Cross sensitivity reaction 22.77 14.21 17 39182 3695 79701494
Transplant rejection 22.66 14.21 37 39162 19400 79685789
Liver transplant rejection 22.48 14.21 16 39183 3232 79701957
Palmoplantar pustulosis 22.31 14.21 9 39190 574 79704615
Dermatitis exfoliative 22.17 14.21 27 39172 10802 79694387
Splenic abscess 22.12 14.21 9 39190 587 79704602
Cat scratch disease 21.83 14.21 8 39191 393 79704796
Shock haemorrhagic 21.80 14.21 37 39162 20023 79685166
Fluid retention 21.73 14.21 4 39195 69805 79635384
Eosinophilic myocarditis 21.59 14.21 11 39188 1211 79703978
Migraine 21.57 14.21 8 39191 87485 79617704
Conductive deafness 21.56 14.21 7 39192 238 79704951
Infection 21.50 14.21 55 39144 241657 79463532
Skin hyperpigmentation 21.48 14.21 22 39177 7281 79697908
Thrombocytopenic purpura 21.45 14.21 14 39185 2455 79702734
Lichenoid keratosis 21.43 14.21 17 39182 4040 79701149
Wrong technique in product usage process 21.41 14.21 5 39194 73870 79631319
Breast discomfort 21.39 14.21 8 39191 416 79704773
Balance disorder 21.27 14.21 11 39188 98846 79606343
Systemic lupus erythematosus 21.26 14.21 17 39182 121132 79584057
Musculoskeletal pain 21.13 14.21 12 39187 102342 79602847
Pulmonary cavitation 21.10 14.21 12 39187 1644 79703545
Respiratory symptom 20.97 14.21 18 39181 4773 79700416
Biopsy liver abnormal 20.72 14.21 8 39191 454 79704735
Pruritus 20.71 14.21 290 38909 394358 79310831
Skin reaction 20.68 14.21 32 39167 16036 79689153
Injection site pain 20.64 14.21 20 39179 129818 79575371
Lymph node abscess 20.53 14.21 5 39194 57 79705132
Mast cell activation syndrome 20.48 14.21 9 39190 711 79704478
Pancreatitis 20.34 14.21 77 39122 68498 79636691
Dry mouth 20.15 14.21 9 39190 88010 79617179
Liver transplant 20.14 14.21 17 39182 4406 79700783
Haemolysis 20.08 14.21 28 39171 12784 79692405
Mastitis bacterial 20.07 14.21 5 39194 63 79705126
Nephropathy toxic 20.03 14.21 36 39163 20383 79684806
Clostridium difficile colitis 19.91 14.21 47 39152 32236 79672953
Coronary artery disease 19.85 14.21 4 39195 65470 79639719
Latent tuberculosis 19.78 14.21 15 39184 3338 79701851
Suicide attempt 19.75 14.21 8 39191 82924 79622265
Therapy naive 19.72 14.21 5 39194 68 79705121
Oropharyngeal pain 19.63 14.21 15 39184 109338 79595851
Rheumatoid factor positive 19.58 14.21 3 39196 59836 79645353
Palpitations 19.56 14.21 20 39179 126590 79578599
Testicular mass 19.46 14.21 5 39194 72 79705117
Limbal swelling 19.32 14.21 4 39195 20 79705169
Blood alkaline phosphatase increased 19.31 14.21 72 39127 63592 79641597
Toxic optic neuropathy 19.27 14.21 10 39189 1143 79704046
Anticoagulation drug level below therapeutic 19.24 14.21 11 39188 1522 79703667
Generalised onset non-motor seizure 19.14 14.21 5 39194 77 79705112
Gastrooesophageal reflux disease 19.10 14.21 14 39185 104232 79600957
Nasal congestion 18.87 14.21 7 39192 76545 79628644
Drug level abnormal 18.85 14.21 7 39192 357 79704832
C-reactive protein increased 18.72 14.21 118 39081 128909 79576280
Axonal neuropathy 18.72 14.21 12 39187 2042 79703147
Unmasking of previously unidentified disease 18.70 14.21 12 39187 2045 79703144
Chromaturia 18.70 14.21 40 39159 25706 79679483
Off label use 18.62 14.21 580 38619 906635 78798554
Drug level increased 18.53 14.21 52 39147 39599 79665590
Marrow hyperplasia 18.51 14.21 11 39188 1637 79703552
Stress 18.45 14.21 8 39191 79604 79625585
Antimicrobial susceptibility test resistant 18.41 14.21 7 39192 381 79704808
Type 2 diabetes mellitus 18.38 14.21 3 39196 57119 79648070
Splenomegaly 18.36 14.21 35 39164 20719 79684470
Purpura non-thrombocytopenic 18.31 14.21 6 39193 210 79704979
Skin odour abnormal 18.26 14.21 12 39187 2129 79703060
Vasculitis necrotising 18.14 14.21 10 39189 1290 79703899
Therapeutic product effect decreased 18.13 14.21 33 39166 163830 79541359
Tuberculous pleurisy 18.12 14.21 8 39191 639 79704550
Trichoglossia 17.98 14.21 8 39191 651 79704538
Renal failure 17.97 14.21 164 39035 200804 79504385
Acute respiratory distress syndrome 17.93 14.21 55 39144 44012 79661177
Pericarditis 17.83 14.21 15 39184 104221 79600968
Aspergillus infection 17.80 14.21 33 39166 19128 79686061
Subacute hepatic failure 17.77 14.21 6 39193 231 79704958
Type III immune complex mediated reaction 17.76 14.21 8 39191 670 79704519
Hypertension 17.75 14.21 93 39106 330899 79374290
Vanishing bile duct syndrome 17.73 14.21 11 39188 1767 79703422
Therapeutic agent-diagnostic test interaction 17.59 14.21 4 39195 33 79705156
Psoas abscess 17.52 14.21 9 39190 1008 79704181
Coagulation factor X level decreased 17.47 14.21 5 39194 110 79705079
Wheezing 17.38 14.21 19 39180 116645 79588544
Human herpesvirus 6 infection 17.31 14.21 17 39182 5353 79699836
Hilar lymphadenopathy 17.28 14.21 11 39188 1848 79703341
Hepatitis A virus test positive 17.28 14.21 4 39195 36 79705153
Cell death 17.28 14.21 16 39183 4683 79700506
Rash erythematous 17.24 14.21 65 39134 57704 79647485
Urinary tract inflammation 17.22 14.21 6 39193 254 79704935
Erythema multiforme 17.16 14.21 31 39168 17620 79687569
Cryptococcosis 17.10 14.21 14 39185 3479 79701710
Upper respiratory tract infection 17.02 14.21 12 39187 91156 79614033
Osteoarthritis 16.96 14.21 11 39188 87298 79617891
Anuria 16.90 14.21 34 39165 20929 79684260
Dyspnoea exertional 16.87 14.21 11 39188 87062 79618127
Chylothorax 16.74 14.21 8 39191 767 79704422
Hepatorenal syndrome 16.66 14.21 15 39184 4234 79700955
Human herpesvirus 7 infection 16.64 14.21 5 39194 131 79705058
Endocarditis bacterial 16.63 14.21 10 39189 1519 79703670
Post treatment Lyme disease syndrome 16.56 14.21 3 39196 6 79705183
Irritable bowel syndrome 16.55 14.21 5 39194 62236 79642953
Granulomatous lymphadenitis 16.52 14.21 6 39193 287 79704902
Tendon disorder 16.50 14.21 19 39180 7167 79698022
Rebound effect 16.42 14.21 19 39180 7207 79697982
Hyperglycaemia 16.40 14.21 7 39192 70328 79634861
Skin test positive 16.30 14.21 9 39190 1165 79704024
Septic embolus 16.30 14.21 11 39188 2040 79703149
Mobility decreased 15.98 14.21 22 39177 122153 79583036
Pulmonary granuloma 15.96 14.21 11 39188 2110 79703079
Candida infection 15.83 14.21 48 39151 38166 79667023
Joint tuberculosis 15.69 14.21 5 39194 160 79705029
Leprosy 15.60 14.21 5 39194 163 79705026
Chronic allograft nephropathy 15.60 14.21 10 39189 1701 79703488
Pseudomembranous colitis 15.46 14.21 16 39183 5358 79699831
Malabsorption from administration site 15.40 14.21 5 39194 170 79705019
Acid fast bacilli infection 15.37 14.21 5 39194 171 79705018
Injection site reaction 15.31 14.21 4 39195 54781 79650408
CD4/CD8 ratio decreased 15.29 14.21 4 39195 62 79705127
Crystalluria 15.19 14.21 8 39191 943 79704246
Speech disorder 15.17 14.21 4 39195 54441 79650748
Atypical mycobacterial lower respiratory tract infection 15.13 14.21 5 39194 180 79705009
Hypermetabolism 15.04 14.21 6 39193 372 79704817
Paradoxical pain 15.03 14.21 3 39196 12 79705177
Renal atrophy 15.01 14.21 10 39189 1815 79703374
Implant site infection 14.81 14.21 10 39189 1855 79703334
Vitamin K decreased 14.73 14.21 4 39195 72 79705117
Inappropriate schedule of product administration 14.70 14.21 27 39172 133601 79571588
Scar excision 14.68 14.21 4 39195 73 79705116
Skin plaque 14.67 14.21 22 39177 10723 79694466
Cardiac disorder 14.62 14.21 7 39192 65750 79639439
Optic atrophy 14.49 14.21 10 39189 1923 79703266
White blood cell count decreased 14.42 14.21 46 39153 188242 79516947
Disease recurrence 14.32 14.21 51 39148 44058 79661131
Synovial cyst 14.31 14.21 21 39178 10044 79695145
Pyroglutamic acidosis 14.26 14.21 8 39191 1068 79704121
Angina bullosa haemorrhagica 14.26 14.21 5 39194 216 79704973
Visual pathway disorder 14.24 14.21 4 39195 82 79705107

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AB02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Antibiotics
ATC J04AM02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04AM07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
ATC J04BA50 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF LEPRA
Drugs for treatment of lepra
ATC J04BA51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF LEPRA
Drugs for treatment of lepra
FDA CS M0019113 Rifamycins
FDA EPC N0000175500 Rifamycin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000904 Antibiotics, Antitubercular
MeSH PA D000995 Antitubercular Agents
MeSH PA D065695 Cytochrome P-450 CYP2B6 Inducers
MeSH PA D065697 Cytochrome P-450 CYP2C19 Inducers
MeSH PA D065696 Cytochrome P-450 CYP2C8 Inducers
MeSH PA D065698 Cytochrome P-450 CYP2C9 Inducers
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007917 Leprostatic Agents
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
CHEBI has role CHEBI:33231 antitubercular agents
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35816 leprostatic drugs
CHEBI has role CHEBI:37416 RNA polymerase inhibitors
CHEBI has role CHEBI:48001 protein synthesis inhibitors
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:59517 DNA synthesis inhibitors
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77318 PXR agonists
CHEBI has role CHEBI:171664 antiamoebic drugs
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Inactive tuberculosis indication 11999007
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Meningococcus carrier indication 170486006
Prevention of Meningococcal Meningitis indication
Inhalational anthrax off-label use 11389007
Staphylococcal infectious disease off-label use 56038003
Leprosy off-label use 81004002 DOID:1024
Cutaneous anthrax off-label use 84980006 DOID:7426
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Atypical mycobacterial infection off-label use 111812000
Anthrax off-label use 409498004 DOID:7427
Multibacillary leprosy off-label use 416257001
Paucibacillary leprosy off-label use 416483009
Single Lesion Paucibacillary Leprosy off-label use
Haemophilus B Influenzae Prevention off-label use
Synergy for Staphylococcal Osteomyelitis off-label use
Nutritional disorder contraindication 2492009 DOID:374
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Jaundice contraindication 18165001
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gout contraindication 90560007 DOID:13189
Anemia due to enzyme deficiency contraindication 111577008
Pancytopenia contraindication 127034005 DOID:12450
Acute hepatic failure contraindication 197270009
Non-infective meningitis contraindication 230155003
Disease of liver contraindication 235856003 DOID:409
Diabetic - poor control contraindication 268519009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Aplastic anemia contraindication 306058006 DOID:12449
Porphyria contraindication 418470004
Diabetic peripheral neuropathy contraindication 424736006
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Prolonged-Severe Nausea and Vomiting contraindication
Chronic Hepatic Disease contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.94 acidic
pKa2 7.23 acidic
pKa3 11.03 acidic
pKa4 11.77 acidic
pKa5 12.55 acidic
pKa6 7.83 Basic
pKa7 1.35 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
ATP-binding cassette sub-family G member 2 Transporter IC50 4.25 CHEMBL
Bile salt export pump Transporter IC50 4.95 CHEMBL
Caspase-1 Enzyme IC50 5.08 DRUG MATRIX
Solute carrier organic anion transporter family member 1B1 Transporter INHIBITOR Ki 5.96 IUPHAR
Lanosterol 14-alpha demethylase Enzyme IC50 4.52 CHEMBL
Solute carrier organic anion transporter family member 1A2 Transporter INHIBITOR Ki 4.29 IUPHAR
Solute carrier organic anion transporter family member 1B3 Transporter INHIBITOR IC50 5.80 IUPHAR
Glutathione S-transferase omega-1 Unclassified IC50 4.12 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor EC50 5.64 CHEMBL
Alpha-synuclein Transporter IC50 5.15 CHEMBL
DNA-directed RNA polymerase subunit beta Enzyme INHIBITOR DRUGBANK CHEMBL
Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme IC50 7.52 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.53 DRUG MATRIX
Bile salt export pump Transporter IC50 4.46 CHEMBL

External reference:

IDSource
4018619 VUID
N0000146932 NUI
D00211 KEGG_DRUG
4018619 VANDF
CHEBI:28077 CHEBI
RFP PDB_CHEM_ID
CHEMBL374478 ChEMBL_ID
2765 IUPHAR_LIGAND_ID
DB01045 DRUGBANK_ID
202953 RXNORM
1197 MMSL
1207 MMSL
5424 MMSL
d00047 MMSL
002789 NDDF
29175007 SNOMEDCT_US
387159009 SNOMEDCT_US
C0035608 UMLSCUI
D012293 MESH_DESCRIPTOR_UI
135398735 PUBCHEM_CID
2323 INN_ID
VJT6J7R4TR UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rifadin HUMAN PRESCRIPTION DRUG LABEL 1 0068-0508 CAPSULE 300 mg ORAL NDA 27 sections
Rifadin HUMAN PRESCRIPTION DRUG LABEL 1 0068-0510 CAPSULE 150 mg ORAL NDA 27 sections
Rifadin IV HUMAN PRESCRIPTION DRUG LABEL 1 0068-0597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV HUMAN PRESCRIPTION DRUG LABEL 1 0068-0597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV HUMAN PRESCRIPTION DRUG LABEL 1 0068-0597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV NOVAPLUS HUMAN PRESCRIPTION DRUG LABEL 1 0068-0599 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV NOVAPLUS HUMAN PRESCRIPTION DRUG LABEL 1 0068-0599 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifadin IV NOVAPLUS HUMAN PRESCRIPTION DRUG LABEL 1 0068-0599 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS NDA 27 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9230 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 26 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0799 CAPSULE 300 mg ORAL ANDA 24 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0799 CAPSULE 300 mg ORAL ANDA 24 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0801 CAPSULE 150 mg ORAL ANDA 24 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0801 CAPSULE 150 mg ORAL ANDA 24 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0527-1315 CAPSULE 300 mg ORAL ANDA 21 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0527-1315 CAPSULE 300 mg ORAL ANDA 21 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0527-1393 CAPSULE 150 mg ORAL ANDA 21 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 0527-1393 CAPSULE 150 mg ORAL ANDA 21 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 0904-5282 CAPSULE 300 mg ORAL ANDA 24 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 0904-5282 CAPSULE 300 mg ORAL ANDA 24 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 17478-151 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 25 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 17478-151 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 600 mg INTRAVENOUS ANDA 25 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 21695-527 CAPSULE 300 mg ORAL ANDA 21 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 24658-801 CAPSULE 150 mg ORAL ANDA 22 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 24658-802 CAPSULE 300 mg ORAL ANDA 22 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 42254-039 CAPSULE 300 mg ORAL ANDA 26 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 42806-799 CAPSULE 300 mg ORAL ANDA 22 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 42806-799 CAPSULE 300 mg ORAL ANDA 22 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 42806-801 CAPSULE 150 mg ORAL ANDA 22 sections
RIFAMPIN HUMAN PRESCRIPTION DRUG LABEL 1 42806-801 CAPSULE 150 mg ORAL ANDA 22 sections
Rifampin HUMAN PRESCRIPTION DRUG LABEL 1 50090-0964 CAPSULE 300 mg ORAL ANDA 25 sections